Law360, New York (August 8, 2011, 7:21 PM EDT) -- ViiV Healthcare Co., a joint venture of GlaxoSmithKline PLC and Pfizer Inc., filed a patent infringement suit against Teva Pharmaceutical Industries Ltd. on Monday in Delaware federal court to stop Teva from making a generic version of HIV drug Epzicom.
ViiV is asking the court to issue an order blocking Israel-based Teva from making a generic version of Epzicom, also known as Kivexa. Teva's proposed generic will infringe a U.S. patent ViiV obtained in 2002, the suit claims.
“ViiV will be irreparably harmed by Teva's infringing activities unless those activities are enjoined by this court,” the complaint said. The suit follows...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!